Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...